Loading clinical trials...
Loading clinical trials...
An Open-label Pilot Protocol to Evaluate the Efficacy of Letermovir for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis
Conditions
Interventions
Letermovir
Valganciclovir
Locations
1
United States
UPMC
Pittsburgh, Pennsylvania, United States
Start Date
December 6, 2021
Primary Completion Date
March 3, 2025
Completion Date
March 3, 2025
Last Updated
July 8, 2025
NCT07046910
NCT05837663
NCT06439342
NCT07235683
NCT06990711
NCT07291258
Lead Sponsor
Fernanda P Silveira, MD, MS
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions